Improved engineering and manufacture of human iPSC-derived CAR-Monocytes for solid cancer immunotherapy
Time: 11:15 am
day: Day Two Track A AM
Details:
- Precise and safe genetic engineering for advanced iPSCs derived cell- and gene- therapies including immunotherapy
- Integration of large multi-modular gene(s) inserts into iPSCs and efficient differentiation to monocytes, resulting in multi-functional and anti-tumour cells
- Development of an iGEM (iPSCs derived genetically engineered monocytes) platform for HER2+ gastric cancer
